We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current LGND market cap is 1.44B. The company's latest EPS is USD 2.9457 and P/E is 27.62.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 43.98M | 26.37M | 34.99M | 28.1M | 30.98M |
| Operating Income | 14.21M | -1.98M | 3.08M | -3.36M | 2.99M |
| Net Income | 41.95M | 2.29M | -10.27M | 18.19M | 86.14M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 120.28M | 186.42M | 314.73M | 196.25M | 131.31M |
| Operating Income | -5.72M | 8.73M | 78.9M | 3.04M | 9.82M |
| Net Income | 629.3M | -2.99M | 57.14M | -33.36M | 52.15M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 811.08M | 758.11M | 769.23M | 787.22M | 913.87M |
| Total Liabilities | 164.76M | 93.21M | 101.33M | 86.3M | 107.35M |
| Total Equity | 646.32M | 664.89M | 667.9M | 700.91M | 806.52M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.49B | 1.36B | 1.3B | 762.67M | 787.22M |
| Total Liabilities | 727.68M | 652.76M | 476.43M | 165.18M | 86.3M |
| Total Equity | 767.23M | 709.53M | 821.16M | 597.49M | 700.91M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 33.95M | 33.87M | 41.51M | 49.58M | 18.73M |
| Investing | 10.55M | 18.11M | -1.4M | -11.68M | -3.78M |
| Financing | -775k | -68.53M | -65.26M | -59.95M | 12.18M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -29.34M | 54.59M | 78.8M | 137.85M | 49.58M |
| Investing | 466.92M | 231.65M | 30.52M | 163.62M | -11.68M |
| Financing | -485.17M | -310.55M | -137.76M | -275.99M | -59.95M |
| Market Cap | 1.44B |
| Price to Earnings Ratio | 27.62 |
| Price to Sales Ratio | 10.97 |
| Price to Cash Ratio | 62.77 |
| Price to Book Ratio | 2.06 |
| Dividend Yield | - |
| Shares Outstanding | 17.71M |
| Average Volume (1 week) | 127.31k |
| Average Volume (1 Month) | 127.31k |
| 52 Week Change | 11.65% |
| 52 Week High | 94.57 |
| 52 Week Low | 49.24 |
| Spread (Intraday) | 4.82 (5.75%) |
| Company Name | Ligand Pharmaceuticals Incorporated |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.ligand.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
